Planned Interim Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesVaclav hejdaM michelle berreyFrederik nevensNareg sagherianAntonio civitareseCheng zouLynda szczechAlexandre louvetKaren prebleIntercept pharmaceuticals incResearch developmentCompany on twitterWarfarinthe international normalized ratioGlobal corporate communicationsWall street

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,. | June 7, 2023

United statesAntonio civitareseKaren prebleFrederik nevensAlexandre louvetLynda szczechNareg sagherianM michelle berreyCheng zouVaclav hejdaResearch developmentGlobenewswire incCompany on twitterIntercept pharmaceuticals incEuropean association for the studyGlobal corporate communications

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nate liabraatenDan calkinsElisa buffingtonBrian stuglikChugai pharmaceutical co ltdDrug administrationBalance sheet to deliver on development milestonesExchange commissionSecura bio incCorporate communicationsRaf and mek programOxford financeDefactinib combination advancingRecurrent low grade serous ovarian cancerPositive dataPlanned interim analysis

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

12.05.2022 - -FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients- -IDMC Unanimously Votes to .

United statesMitchell steinerSamuel fischEli lillySexual health divisionData monitoring committeeAr prostate cancer programCompany to host investor conference callExchange commissionCompany formCorporate communicationsBreast cancer programVeru incAbemaciclib combination therapyMetastatic breast cancerHost investor conference call today